ALPMY News and Press, Astellas Pharma Inc. ADR From 06/01/22

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology PR Newswire - Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass. , June 1,...

Generic drugmaker Amphastar Pharmaceuticals (NASDAQ:AMPH) announced on Monday that the FDA approved its Abbreviated New Drug Application ("ANDA") for Regadenoson, a bioequivalent and therapeutically equivalent to Lexiscan developed by Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY). Regadenoson i...

Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth. The current share price is very undervalued considering the long term growth prospects. For further details see: Takeda Pharmac...

TFFP is a platform company with leading technology. Clinical/FDA risk is extremely low. The stock is drastically undervalued based on only fraction of the pipeline and multiples of upside. Multiple insider purchases support the bull case and timing. For further details s...

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress PR Newswire Abstracts represent exciting research progress across four cancers where patients have limited treatment options TOKYO , May...

Twist Bioscience (NASDAQ:TWST) said it signed a collaboration and exclusive option license agreement with Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) for antibodies to reduce tumor microenvironment-mediated immunosuppression. Under the agreement, the companies will jointly conduct resear...

Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual Meeting PR Newswire Astellas' investigational nonhormonal treatment meets all primary endpoi...

Astellas Pharma, Inc. (ALPMF) Q4 2022 Results Conference Call April 27, 2022 01:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Kenji Yasukawa - President and CEO Bernie Zeiher - Chief Medical Officer Yukio Matsui - Chief Commercial Officer Minoru Kikuok...

University of Tokyo, Astellas Enter Second Phase of Strategic Partnership for Co-creation of Innovative New Medicines and Medical Solutions PR Newswire TOKYO , April 25, 2022 /PRNewswire/ -- The University of Tokyo (President: Teruo Fujii , P...

European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer PR Newswire - Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior platinum-containing chemotherapy and a PD...